Risk of strong antibody decline in dialysis and transplant patients after SARS-CoV-2mRNA vaccination: Six months data from the observational Dia-Vacc study

• Egile Nagusiak: Julian Stumpf (Egilea), Jörg Schwöbel (Egilea), Tom Lindner (Egilea), Leona Anders (Egilea), Torsten Siepmann (Egilea), Claudia Karger (Egilea), Jan Hüther (Egilea), Heike Martin (Egilea), Petra Müller (Egilea), Robert Faulhaber-Walter (Egilea), Torsten Langer (Egilea), Holger Schirutschke (Egilea), Thomas Stehr (Egilea), Frank Meistring (Egilea), Annegret Pietzonka (Egilea), Kirsten Anding-Rost (Egilea), Katja Escher (Egilea), Frank Pistrosch (Egilea), Jens Schewe (Egilea), Harald Seidel (Egilea), Kerstin Barnett (Egilea), Thilo Pluntke (Egilea), Simon Cerny (Egilea), Alexander Paliege (Egilea), Ingolf Bast (Egilea), Anne Steglich (Egilea), Florian Gembardt (Egilea), Friederike Kessel (Egilea), Hannah Kröger (Egilea), Patrick Arndt (Egilea), Jan Sradnick (Egilea), Kerstin Frank (Egilea), Anna Klimova (Egilea), René Mauer (Egilea), Xina Grählert (Egilea), Torsten Tonn (Egilea), Christian Hugo (Egilea)
• Formatua: Liburua
• Argitaratua: Elsevier, 2022-06-01T00:00:00Z.
• Gaiak: article
• Sarrera elektronikoa: Connect to this object online.

Summary: Background: Vulnerable dialysis and kidney transplant patients show impaired seroconversion rates compared to medical personnel eight weeks after SARS-CoV-2mRNA vaccination. Methods: We evaluated six months follow up data in our observational Dia-Vacc study exploring specific cellular (inte...